CYCLOPHARM LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.76 AUD | 0.00% |
|
+0.57% | -8.57% |
| Mar. 19 | Cyclopharm's Technegas Device Carries Out Imaging of First US Patients | MT |
| Mar. 18 | Cyclopharm Limited(ASX:CYC) added to S&P/ASX All Ordinaries Index | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The group's high margin levels account for strong profits.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.57% | 109M | - | ||
| +8.69% | 220B | B | ||
| +6.69% | 183B | B- | ||
| +10.90% | 133B | B- | ||
| +25.41% | 107B | A- | ||
| +0.27% | 63.05B | A- | ||
| +12.72% | 51.74B | B+ | ||
| +3.96% | 50.47B | B+ | ||
| +0.40% | 40.91B | A | ||
| +15.03% | 40.59B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CYC Stock
- Ratings Cyclopharm Limited
